Selected clinical characteristics of patients with pSS. Except for proportions, results are expressed as mean ± SD.
| pSS/Lung Disease, n = 5 | pSS n = 15 | p | |
|---|---|---|---|
| Female, n (%) | 5 (100) | 15 (100) | — |
| Age, yrs | 47.6 ± 19 | 53.6 ± 13 | — |
| Disease duration, yrs | 6.8 ± 4 | 4.6 ± 2.6 | — |
| Xerostomia, n (%) | 5 (100) | 15 (100) | — |
| Keratoconjunctivitis, n (%) | 4 (80) | 15 (100) | — |
| Salivary gland biopsy, n (%) | 4/4 (100) | 5/5 (100) | — |
| Leukocytes, 103/μl | 6.96 ± 1.8 | 6.5 ± 1.9 | — |
| Neutrophils, 103/μl | 4.12 ± 1.5 | 4.06 ± 1.4 | — |
| Lymphocytes, 103/μl | 1.97 ± 0.4 | 1.82 ± 0.6 | — |
| Monocytes, 103/μl | 0.45 ± 0.3 | 0.5 ± 0.1 | — |
| Eosinophils, 103/μl | 0.37 ± 0.2 | 0.29 ± 0.2 | — |
| Hemoglobin, g/dl | 14.2 ± 1.4 | 14.1 ± 0.9 | — |
| Platelets, 103/μl | 266 ± 47 | 226 ± 56 | — |
| ESR, mm/h | 16.2 ± 7 | 28.3 ± 16 | — |
| Rheumatoid factor +, n (%) | 5 (100) | 7 (47) | 0.03 |
| Antinuclear antibodies +, n (%) | 3 (60) | 11 (73) | — |
| Anti-Ro/SSA +, n (%) | 1 (20) | 6 (40) | — |
| Anti-La/SSB +, n (%) | 1 (20) | 5 (33) | — |
| Anti-CCP2 +, n (%) | 0 (0) | 0 (0) | — |
| C3 complement*, mg/dl | 135 ± 25 | 115 ± 23 | — |
| C4 complement*, mg/dl | 21 ± 7 | 22 ± 6 | — |
| Antimalarials, n (%) | 4 (80) | 14 (93) | — |
| Prednisone, n (%) | 2 (40) | 2 (13) | — |
↵* Normal range for C3 complement, 79–152 mg/dl; C4 complement, 16–38 mg/dl. ESR: erythrocyte sedimentation rate; Anti-CCP2: 2nd generation anti-cyclic citrullinated peptide antibodies.